# Identification of Pathways to Mitigate Immune-Related Adverse Events With Cancer Immunotherapy

> **NCT04283539** · — · UNKNOWN · sponsor: **National Jewish Health** · enrollment: 238 (estimated)

## Conditions studied

- Cancer

## Interventions

- **DRUG:** systemic corticosteroid or biologic

## Key facts

- **NCT ID:** NCT04283539
- **Lead sponsor:** National Jewish Health
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-06-01
- **Primary completion:** 2024-06
- **Final completion:** 2025-02
- **Target enrollment:** 238 (ESTIMATED)
- **Last updated:** 2023-11-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04283539

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04283539, "Identification of Pathways to Mitigate Immune-Related Adverse Events With Cancer Immunotherapy". Retrieved via AI Analytics 2026-09-04 from https://api.ai-analytics.org/clinical/NCT04283539. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*